Patent · US Active

Compositions for preventing and/or treating pathological conditions associated with alpha-glucosidase

US10500245B2 · kind B2 · utility

0Cited by

2References

5Claims

0Family size

Assignees

UNIVERSITE DE LA ROCHELLE · FR
UNIVERSITE CLERMONT AUVERGNE · FR

Inventors

Thierry Maugard · La Jarne, FR
Stephanie Bordenave-Juchereau · Rochefort, FR
Jean-Marie Piot · Villeneuve-d'Ascq, FR
Yesmine Ben-Henda · La Rochelle, FR
Pascal Sirvent · Chamalières, FR
Sebastien Peltier · Soumard, FR

Key dates

Filing date	Feb 18, 2015
Grant date	Dec 10, 2019
Priority date	—
Expiry date	Feb 18, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA23V2002/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A composition including at least one XAP peptide, in which X represents the empty set or a valine, for use in the prevention and/or treatment of pathologies associated with alpha-glucosidase. Also, the use of a hydrolysate of at least one protein, the protein including or constituted by at least 0.05% to <5% or of at least 5% of XAP units, in which X represents the empty set or a valine, for use in the prevention and/or treatment of pathologies associated with alpha-glucosidase.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.